awmsg logo



adalimumab (Humira®)


Reference No. 1977

Publication date:
15/08/2013


Appraisal information

adalimumab (Humira®) 40 mg solution for injection


Company: AbbVie Ltd
BNF category: Musculoskeletal and joint diseases
NMG meeting date: 19/06/2013
AWMSG meeting date: 17/07/2013
   
   
Submission Type: Limited Submission
Status: Superseded
Advice No: 2113
Ministerial ratification: 14/08/2013

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

AWMSG ADVICE SUPERSEDED BY NICE GUIDANCE (TA373) NICE GUIDANCE ISSUED DECEMBER 2015 (Refer to NICE website for full guidance on NICE recommendations, including any specific restrictions on the use of the technology) Adalimumab (Humira®) is recommended as an option for use within NHS Wales, in combination with methotrexate, for the treatment of active polyarticular juvenile idiopathic arthritis, in children aged 2 to 4 years who have had an inadequate response to one or more disease-modifying anti-rheumatic drugs (DMARDs). Adalimumab can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate. Adalimumab has not been studied in children aged less than 2 years.
Final Appraisal Recommendation (FAR)
Download
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download